FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

New Orphan Product Grant Funding Opportunity

FDA releases a funding opportunity for natural history studies to advance product development in rare diseases and conditions.

latest-news-card-1
Human Drugs

7 Observations in Natco Pharma FDA-483

FDA releases the form FDA-483 with seven observations from an inspection at Indias Natco Pharma.

latest-news-card-1
Human Drugs

Guide to Characterize Combination Cancer Drugs

FDA publishes a draft guidance on characterizing the effects of some oncology drugs when used in combination with other drugs.

latest-news-card-1
Human Drugs

Fast Track Status for Zenith NUT Cancer Drug

FDA grants Zenith Epigenetics a fast-track designation for its ZEN-3694 and its use for treating metastatic or unresectable NUT carcinoma in patients ...

latest-news-card-1
Human Drugs

Reviewers Question Otsuka PTSD Drug Efficacy

FDA medical reviewers question the demonstration of efficacy in an Otsuka NDA for a combination of Rexulti and Zoloft to treat PTSD.

latest-news-card-1
Human Drugs

Partial Hold on Kezars Zetomipzomib Lifted

FDA lifts a partial clinical hold against Kezar Life Sciences and its completed PORTOLA Phase 2a clinical trial evaluating zetomipzomib in patients wi...

latest-news-card-1
FDA General

HHS Finalizes FDA Employee Terminations

HHS notifies over 3,000 FDA employees that their employment has been officially terminated effective 7/14.

latest-news-card-1
Human Drugs

CGMP Violations Cited in Daewoo Warning

FDA warns South Koreas Daewoo Pharmaceutical Co. about CGMP violations in its production of finished drugs.

latest-news-card-1
Human Drugs

FDA Inspection Backlog Can Hurt Canada: Analysis

A Benefits Pensions Monitor report says FDA drug inspection backlogs can hurt Canada since FDA has been performing 70% of Canadas drug manufacturing i...

latest-news-card-1
Human Drugs

Ocular Toxicity Concerns with Multiple Myeloma Drug: FDA

FDA reviewers plan to ask an advisory committee this week about its concerns with ocular toxicity seen in trial data submitted by GSK in its BLA for B...